KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Change in Acquisitions & Divestments: 2018-2024

Historic Change in Acquisitions & Divestments for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $19.8 million.

  • Royalty Pharma's Change in Acquisitions & Divestments changed negligibly% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year decrease of 2.09%. This contributed to the annual value of $19.8 million for FY2024, which is 18.88% down from last year.
  • According to the latest figures from FY2024, Royalty Pharma's Change in Acquisitions & Divestments is $19.8 million, which was down 18.88% from $24.4 million recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Change in Acquisitions & Divestments ranged from a high of $1.6 billion in FY2021 and a low of $19.8 million during FY2024.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $24.4 million (2023), whereas its average is $278.8 million.
  • As far as peak fluctuations go, Royalty Pharma's Change in Acquisitions & Divestments skyrocketed by 95.95% in 2021, and later plummeted by 96.92% in 2023.
  • Yearly analysis of 5 years shows Royalty Pharma's Change in Acquisitions & Divestments stood at $815.4 million in 2020, then spiked by 95.95% to $1.6 billion in 2021, then tumbled by 50.41% to $792.3 million in 2022, then tumbled by 96.92% to $24.4 million in 2023, then dropped by 18.88% to $19.8 million in 2024.